MAGEA3 and non-small cell lung carcinoma: This trial evaluates the safety and efficacy of combining two investigational therapies—Ad-MAGEA3 and MG1-MAGEA3—with pembrolizumab in patients with NSCLC who have previously undergone standard treatment.